

TEKLA LIFE SCIENCES INVESTORS

Notification of Sources of Distribution

Distribution Paid Date: June 30, 2021

Distribution Amount Per Common Share: \$0.41

The following table sets forth the estimated amounts of the current distribution, paid June 30, 2021, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source. All amounts are expressed per common share.

	Current Distribution	Percentage Breakdown of Current Distribution	Total Cumulative Distributions for the Fiscal Year to Date ¹	Percentage Breakdown of the Total Cumulative Distributions for the Fiscal Year to Date ¹
Net Investment Income	\$0.0000	0%	\$0.0000	0%
Net Realized ST Cap Gains	\$0.0000	0%	\$0.4143	33%
Net Realized LT Cap Gains	\$0.4100	100%	\$0.8457	67%
Return of Capital or Other Capital Source	\$0.0000	0%	\$0.0000	0%
TOTAL (per common share):	\$0.4100	100%	\$1.2600	100%

The table below includes information relating to the Fund's performance based on its NAV for certain periods.

Average annual total return at NAV for the period from April 30, 2016 through April 30, 2021	12.24%
Annualized current distribution rate expressed as a percentage of NAV as of April 30, 2021	7.69%
Cumulative total return at NAV for the fiscal year, through April 30, 2021 ²	9.90%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of April 30, 2021 ¹	5.90%

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's managed distribution policy.

The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is \$184,606,472, of which \$148,920,583 represents net unrealized appreciation of portfolio securities.

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

¹The Fund's current fiscal year began on October 1, 2020.

²Cumulative total return at NAV is the percentage change in the Fund's NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2020 through April 30, 2021.

Tekla Life Sciences Investors
CUSIP: 87911K100
www.teklacap.com

Tekla Capital Management LLC
100 Federal Street, 19th Floor
Boston, Massachusetts 02110

617-772-8500
Fax: 617-772-8577